PHARMAS CRUSHED BY THE NOVO SPELL

02/01/25 -"Pharmas closed the year with a dreadful performance, itself the reflection of dashed excessive hopes for GLP-1 developments. The unwarranted Novo Nordisk collapse on 19-12 on a marginal miss in its ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

02/01/25

Download

You may also be interested by these reports :

04/07/25

United Utilities

EPS spiked after 2024 because UU is entering a new 5-year regulatory period (AMP8) during which it is allowed to charge more for its services. This ...

01/07/25

BKW AG

We anticipate solid 1H results but valuation doesn’t look cheap

01/07/25

FCC

Our 2025 and 2026 EPS forecasts have been upgraded despite the spin-off due to FCC’s continuing operations having delivered stronger profitability ...

26/06/25

Veolia

We met with Veolia’s management yesterday during its Deep Dive on hazardous waste, the latest in a series of such events since the launch of GreenUp ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue

EDP